Therapy News and Research

RSS

Liposorber LA-15 System to treat pediatric patients with primary FSGS gets FDA approval

The U.S. Food and Drug Administration today approved Liposorber LA-15 System to treat pediatric patients with primary focal segmental glomerulosclerosis either before transplant, or after renal (kidney) transplantation in which there is recurrence of FSGS.

11 Oct 2013

Diverse Neurological Disorders Appear To Share Tangled Metabolic Roots

...

10 Oct 2013

Teva Cutting 5,000 Jobs In Global Restructuring

...

10 Oct 2013

Nuvo Scores $2M Payment From Galderma For Launch Of Topical Anesthetic In Brazil

...

10 Oct 2013

Combining gene therapy with stem cells leads to faster healing of burns

Johns Hopkins researchers, working with elderly mice, have determined that combining gene therapy with an extra boost of the same stem cells the body already uses to repair itself leads to faster healing of burns and greater blood flow to the site of the wound.

10 Oct 2013

Patients who received care at multiple HIV clinics have higher HIV viral loads

Patients who received care at multiple HIV clinics—as opposed to only one— were less likely to take their medication and had higher HIV viral loads, a new study published in the journal AIDS and Behavior of almost 13,000 HIV patients in Philadelphia from Penn Medicine found.

10 Oct 2013

Beta-blocker therapy controls heart rate, improves cardiovascular performance in septic shock patients

Andrea Morelli, M.D., of the University of Rome, Italy, and colleagues conducted a study to investigate the effect of the short-acting beta-blocker esmolol on the heart rate of patients with severe septic shock and high risk of death.

10 Oct 2013

Phase 3 study of idelalisibin reports positive results in CLL patients

Following a recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early.

10 Oct 2013

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced today the continuation of the development program of Lu AE58054 for the treatment of Alzheimer's disease, initiating the first out of four phase III clinical trials with the compound.

10 Oct 2013

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer Inc. announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111).

10 Oct 2013

Gene mutation offers clues to development of diverse neurological disorders

A research team, headed by Theodore Friedmann, MD, professor of pediatrics at the University of California, San Diego School of Medicine, says a gene mutation that causes a rare but devastating neurological disorder known as Lesch-Nyhan syndrome appears to offer clues to the developmental and neuronal defects found in other, diverse neurological disorders like Alzheimer's, Parkinson's and Huntington's diseases.

10 Oct 2013

Team Ritter to raise funds for John Ritter Foundation for Aortic Health at ING NYC Marathon

Friends and family members of people with thoracic aortic disease and fans of the late legendary comedic actor John Ritter will come together as Team Ritter to raise funds for the John Ritter Foundation for Aortic Health at the ING New York City Marathon on Nov. 3, 2013.

10 Oct 2013

Theraclion unveils very positive initial clinical results in treatment of thyroid nodules

Theraclion, a company specializing in advanced medical equipment for echotherapy (or ultrasound therapy), has unveiled very positive initial clinical results in the treatment of thyroid nodules. These findings demonstrate the effectiveness of its Echopulse device in the treatment of this condition.

10 Oct 2013

Possible topical treatment for age-related macular degeneration identified by Tufts researchers

Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration in a study of mice that shows promise for clinical use.

10 Oct 2013

Hypertension affects over 40% of Chinese adults, shows WHO report

With a recent World Health Organization report showing hypertension affects over 40% of Chinese adults aged 45 or older, combating high blood pressure will be high on the agenda of the 24th Great Wall International Congress of Cardiology & Asia Pacific Heart Congress, in Beijing (10 to 13 October 2013).

10 Oct 2013

CAC receives $1M grant to render services to young sexual assault victims

The Orange County Children's Advocacy Center (CAC) has been awarded a grant of nearly $1 million to help close gaps in existing services to young sexual assault victims.

10 Oct 2013

Receiving care at several HIV clinics may increase medication errors

Patients who received care at multiple HIV clinics-as opposed to only one- were less likely to take their medication and had higher HIV viral loads, a new study published in the journal AIDS and Behavior of almost 13,000 HIV patients in Philadelphia from Penn Medicine found.

10 Oct 2013

Key findings may have broad implications for future scleroderma therapy

The Scleroderma Research Foundation today said that researchers at The Johns Hopkins University working in a novel mouse model of Stiff Skin Syndrome have made key discoveries that may have broad implications for future scleroderma therapy.

10 Oct 2013

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin two Phase II clinical studies of ALG-1001.

10 Oct 2013

Dry eye disease symptom change independent of tear osmolarity

Tear osmolarity is a poor indicator of treatment response in patients with dry eye disease (DED), suggests research published in the American Journal of Ophthalmology.

9 Oct 2013

Therapy News and Research

Liposorber LA-15 System to treat pediatric patients with primary FSGS gets FDA approval

Diverse Neurological Disorders Appear To Share Tangled Metabolic Roots

Teva Cutting 5,000 Jobs In Global Restructuring

Nuvo Scores $2M Payment From Galderma For Launch Of Topical Anesthetic In Brazil

Combining gene therapy with stem cells leads to faster healing of burns

Patients who received care at multiple HIV clinics have higher HIV viral loads

Beta-blocker therapy controls heart rate, improves cardiovascular performance in septic shock patients

Phase 3 study of idelalisibin reports positive results in CLL patients

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Gene mutation offers clues to development of diverse neurological disorders

Team Ritter to raise funds for John Ritter Foundation for Aortic Health at ING NYC Marathon

Theraclion unveils very positive initial clinical results in treatment of thyroid nodules

Possible topical treatment for age-related macular degeneration identified by Tufts researchers

Hypertension affects over 40% of Chinese adults, shows WHO report

CAC receives $1M grant to render services to young sexual assault victims

Receiving care at several HIV clinics may increase medication errors

Key findings may have broad implications for future scleroderma therapy

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Dry eye disease symptom change independent of tear osmolarity

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News